How would you design a vaccine that protects against HIV...

Key Concepts

Vaccine Platform Design

This concept involves selecting a method to deliver viral antigens safely to the immune system without risking infection. Common platforms include subunit vaccines that use purified proteins, nucleic acid vaccines like mRNA or DNA that instruct cells to produce the antigen, and viral vector vaccines that utilize replication-incompetent viruses to carry HIV antigens. The choice of platform is crucial for both the effectiveness of the immune response and the safety profile of the vaccine.

Antigen Engineering

Antigen engineering refers to the process of identifying and modifying specific viral proteins or peptides to elicit a protective immune response. For HIV, this means targeting regions that are essential for viral function and are conserved across different strains, thereby overcoming the challenge of high mutation rates. Engineered antigens can be designed to present the immune system with a clear and safe target, improving vaccine efficacy.

Immune Activation and Response

A fundamental principle of vaccine development is to stimulate a balanced and robust immune response that includes both humoral (antibody-mediated) and cellular (T cell-mediated) components. This dual activation is essential for neutralizing the virus on entry and eliminating infected cells, thereby offering comprehensive protection. The vaccine must mimic natural infection cues without causing disease.

Safety Considerations in Vaccine Design

Safety is a core tenet in vaccine development, particularly for diseases like HIV. By using non-replicative platforms such as inactivated viruses, subunit components, or replication-incompetent vectors, developers ensure that the vaccine cannot infect the patient. This concept underpins the design strategies that focus on eliminating any risk of the vaccine causing disease, while still eliciting an effective immune response.

Transcript

00:01 So today we have problem 19, which is about how would you design a vaccine that protects against hiv infection without the possibility of infecting the patients.

00:13 Well, some key points, i must mention some key points first.

00:19 Another researchers have been working on an hiv vaccine since 1980s, but progress towards an effective vaccine has been much slower than anticipated.

00:30 So the finding at least, you know, a partially effective vaccine remains of critical importance for the hiv response.

00:42 The biggest reduction in few infections would be achieved by a combination of prep.

00:48 When i'm saying prp, it means that pre -exposure prophylexes, okay? so, prep, universal, anti -retro -viral, you know, treatment for the people already living with hiv and a vaccine.

01:10 Then we have an hiv is more realistic and optimistic forecast, you know, prospect today than a decade ago.

01:20 And an optimistic forecast of hiv vaccine availability is that one might be available.

01:27 By, you know, 2030.

01:34 So what is an actually hiv vaccine? today, an effective vaccine against hiv does not exist.

01:44 A vaccine that can prevent infection would infect the immune system to respond, you know, to hiv by making antibodies that can bind the virus and stop it from infecting cells or by promoting other immune responses that kill the virus.

02:04 So no vaccine is 100 % effective and this is likely to be the same for hiv.

02:13 Some people who receive a vaccine will not respond strongly enough to the vaccine and will not be protected as in the case of the seasonal flow and vaccine.

02:23 So the need for a vaccine against hiv is another big.

02:29 Step over here in our discussion.

02:32 You know, un aids estimate that prox 1 .8 million people became infected with hiv in 2017, whereas 36 .9 million people were living with hiv and 21 .7 people were, you know, receiving anti -retroviolet therapy.

02:56 So despite dramatic improvements in access to anti -retro viral therapy and evidence in some regions of the world that treatments carp up has resulted in a reduction in new hiv infection...

Please give Ace some feedback